BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16424055)

  • 1. Vaccine with beta-defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses.
    Ma XT; Xu B; An LL; Dong CY; Lin YM; Shi Y; Wu KF
    Cancer Res; 2006 Jan; 66(2):1169-76. PubMed ID: 16424055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antileukemia effect of combinational gene therapy using murine beta-defensin 2 and IL-18 in L1210 murine leukemia model.
    Xu B; Dong CY; Zhang F; Lin YM; Wu KF; Ma XT
    Gene Ther; 2007 Aug; 14(15):1181-7. PubMed ID: 17495947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
    Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
    Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1.
    Wang YS; Wang GQ; Wen YJ; Wang L; Chen XC; Chen P; Kan B; Li J; Huang C; Lu Y; Zhou Q; Xu N; Li D; Fan LY; Yi T; Wu HB; Wei YQ
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6779-87. PubMed ID: 18006780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
    Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
    Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease.
    Gu T; Kilinc MO; Egilmez NK
    Cancer Immunol Immunother; 2008 Jul; 57(7):997-1005. PubMed ID: 18049819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    Cancer Immunol Immunother; 2006 Apr; 55(4):420-32. PubMed ID: 16025264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines.
    Park HJ; Qin H; Cha SC; Sharma R; Chung Y; Schluns KS; Neelapu SS; Overwijk WW; Hwu P; Kwak LW
    Vaccine; 2011 Apr; 29(18):3476-82. PubMed ID: 21382485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
    Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
    Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model.
    Doolan DL; Hoffman SL
    J Immunol; 1999 Jul; 163(2):884-92. PubMed ID: 10395683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-defensin 2 as an adjuvant promotes anti-melanoma immune responses and inhibits the growth of implanted murine melanoma in vivo.
    Mei HF; Jin XB; Zhu JY; Zeng AH; Wu Q; Lu XM; Li XB; Shen J
    PLoS One; 2012; 7(2):e31328. PubMed ID: 22348070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):191-201. PubMed ID: 7905286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
    Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
    J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia.
    Saudemont A; Buffenoir G; Denys A; Desreumaux P; Jouy N; Hetuin D; Bauters F; Fenaux P; Quesnel B
    Leukemia; 2002 Sep; 16(9):1637-44. PubMed ID: 12200675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
    Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
    J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.